Aino Health AB (publ)

Aino Health AB (publ), a Swedish company based in Stockholm, specializes in delivering comprehensive corporate health management solutions to both private and public organizations throughout Finland. Their flagship offering is HealthManager, a Software-as-a-Service (SaaS) platform equipped with tools for health surveys, analytical insights, exposure checks, and compliance with security and GDPR regulations, along with an integrated e-learning module. Beyond the software, Aino Health provides a range of additional services, including telemedicine, professional support (such as analytics, management/employee guidance, and well-being programs), and onboarding assistance covering project management, implementation, and training. The company also extends its services to a diverse network of partners, including occupational health providers, insurance companies, IT firms, HR/payroll service centers, and various healthcare practitioners.

Aino Health AB (publ) trades as AINO.ST on STO. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in SEK.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Aino Health AB (publ) can be compared against peers such as 2cureX AB (publ), Episurf Medical AB (publ), ExpreS2ion Biotech Holding AB (publ), Guard Therapeutics International AB (publ), Modus Therapeutics Holding AB (publ), ODI Pharma AB.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $28.23M, beta of 2.66, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

AINO.ST currently shows total debt of N/A and beta of 2.66. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.ainohealth.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.